Blueprint Medicines (BPMC) | Stock Overview & Key Data
Blueprint Medicines Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $129.65 on July 16, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Mar 31, 2025
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Blueprint Medicines
BPMC
|
8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 61.42% | 61.42% | 12.60% | 149.54% | 73.38% | 370.76% | 598.65% | 598.65% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.49% | -1.11% | -12.54% | -1.86% | -5.98% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -5.03% | -15.02% | -23.79% | -18.77% | -22.36% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
BridgeBio Pharma
BBIO
|
14.21B Large-cap | -5.68% | -7.41% | -2.47% | -10.61% | -18.35% | 93.46% | 364.66% | 14.32% | 145.68% | 145.68% | 145.68% |
|
Bio-Techne
TECH
|
9.07B Mid-cap | 3.75% | -9.08% | -13.92% | -20.94% | -16.56% | 6.78% | -37.73% | -51.28% | 86.91% | 161.27% | 281.12% |
|
Roivant Sciences
ROIV
|
20.14B Large-cap | -4.75% | -0.35% | 0.57% | 40.60% | 28.86% | 172.88% | 217.69% | 203.85% | 202.32% | 202.32% | 202.32% |
Ownership & Short Interest
Calculate Your Blueprint Medicines Investment Returns
Long-Term Investment Performance Analysis
Blueprint Medicines stock price in May 2016 was $20.36, A $1,000.00 lump sum investment in Blueprint Medicines made 9 years ago would be worth approximately $6,358.55 today, representing a exceptional return of 535.85%. This translates to an annualized return (CAGR) of 22.45%.
9 Years 1 Month Investment Scenario (May 2016 - Jul 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BPMC's 52-week high and low?
- In the last 52 weeks, Blueprint Medicines reached a high of $129.65 (on July 16, 2025) and a low of $73.04 (on April 9, 2025).
- What is the market cap and P/E ratio for BPMC?
- Curious about Blueprint Medicines's size and valuation? Its market capitalization stands at 8.37B. When it comes to valuation, the P/E ratio (trailing twelve months) is -120.99, and the forward P/E (looking ahead) is -137.72.
- Does BPMC pay dividends? If so, what's the yield?
- As for dividends, Blueprint Medicines isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Blueprint Medicines's main competitors or similar companies to consider before investing?
When looking at Blueprint Medicines, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% BridgeBio Pharma
BBIO14.21B Healthcare Biotechnology 93.46% 364.66% Bio-Techne
TECH9.07B Healthcare Biotechnology 6.78% -37.73% Roivant Sciences
ROIV20.14B Healthcare Biotechnology 172.88% 217.69% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Blueprint Medicines Corp.? (e.g., ROE, Debt/Equity)
- To get a sense of Blueprint Medicines's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -47.71%, the Debt to Equity ratio from the most recent quarter is 208.50, and its Gross Profit Margin stands at 98.12%.
- What is the recent revenue and earnings growth for BPMC?
- Looking at Blueprint Medicines's growth, its revenue over the trailing twelve months (TTM) was $562M. Compared to the same quarter last year (YoY), quarterly revenue grew by 55.50%, and quarterly earnings saw a YoY growth of -99.40%.
- How much of BPMC stock is held by insiders and institutions?
- Wondering who owns Blueprint Medicines stock? Company insiders (like executives and directors) hold about 0.88% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 109.19%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.